Skip to main content
. 2011 Apr;43(2):126–130. doi: 10.4103/0253-7613.77341

Table 2.

Spectrum of suspected adverse drug reactions of nanoparticle versus conventional paclitaxel formulation

graphic file with name IJPharm-43-126-g002.jpg